Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:asfotase_alfa
|
| gptkbp:approvalYear |
2015-10-23
|
| gptkbp:ATCCode |
A16AB12
|
| gptkbp:CASNumber |
947604-94-2
|
| gptkbp:chemicalFormula |
C1998H3088N562O637S32
|
| gptkbp:EMAApprovalDate |
2015-08-28
|
| gptkbp:form |
solution for injection
|
| gptkbp:genericName |
gptkb:asfotase_alfa
|
| https://www.w3.org/2000/01/rdf-schema#label |
Strensiq
|
| gptkbp:indication |
treatment of hypophosphatasia
perinatal/infantile- and juvenile-onset hypophosphatasia |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Alexion_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
enzyme replacement therapy
|
| gptkbp:orphanDrugStatus |
yes
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescriptionRequired |
https://www.strensiq.com/
|
| gptkbp:routeOfAdministration |
subcutaneous
intravenous |
| gptkbp:sideEffect |
fever
headache injection site reaction hypersensitivity |
| gptkbp:storage |
2°C to 8°C
|
| gptkbp:bfsParent |
gptkb:Alexion_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|